Shoji Tetsuo, Kabata Daijiro, Nagakura Yu, Nakatani Shinya, Uedono Hideki, Nagata Yuki, Fujii Hisako, Mori Katsuhito, Imanishi Yasuo, Morioka Tomoaki, Emoto Masanori
Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, 545-8585, Japan.
Department of Vascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, 545-8585, Japan.
Clin Exp Nephrol. 2025 Jul 17. doi: 10.1007/s10157-025-02735-3.
T50 calciprotein crystallization test (serum calcification propensity, T50) is a blood test which assesses the resistance of the serum to calcification stress in vitro. Because of its limited availability in clinical practice of chronic kidney disease, we aimed to develop equations for estimated T50 (eT50).
This was an observational study in 1,651 hemodialysis patients whose T50 was measured by the method Pasch et al. The data sets were divided into two groups for the derivation (N = 1,003) and validation (N = 648) of the equations. Logarithmically transformed values of measured T50 were regressed by relevant variables selected from 36 candidates based on the Akaike's Information Criteria.
Because the initial model A included 19 variables, we developed simpler models B and C with 10 and 5 variables, respectively, for clinical use. All these models included serum phosphate, magnesium, sodium, chloride, and total ion binding capacity. When these equations were validated, the intercept, slope, and R values were 1.130, 0.770, 0.596 for model A, 1.093, 0.782, and 0.597 for model B, and 0.979, 0.806, and 0.573 for model C, respectively. Multivariable-adjusted Fine-Gray analysis showed that a lower eT50 value by model A, B, or model C was an independent predictor of a higher risk of new cardiovascular events in the total cohort as the measured T50 was.
We developed three equations for eT50 from clinically available variables. These eT50 values may be useful if measured T50 is not available.
T50 钙蛋白结晶试验(血清钙化倾向,T50)是一项血液检测,用于评估血清在体外对钙化应激的抵抗能力。由于其在慢性肾脏病临床实践中的可用性有限,我们旨在开发估算 T50(eT50)的方程。
这是一项对 1651 例血液透析患者的观察性研究,其 T50 通过 Pasch 等人的方法进行测量。数据集被分为两组,用于方程的推导(N = 1003)和验证(N = 648)。根据赤池信息准则从 36 个候选变量中选择相关变量,对测量的 T50 的对数转换值进行回归分析。
由于初始模型 A 包含 19 个变量,我们分别开发了更简单的模型 B 和模型 C,分别包含 10 个和 5 个变量以供临床使用。所有这些模型都包括血清磷酸盐、镁、钠、氯和总离子结合能力。当对这些方程进行验证时,模型 A 的截距、斜率和 R 值分别为 1.130、0.770、0.596,模型 B 为 1.093、0.782 和 0.597,模型 C 为 0.979、0.806 和 0.573。多变量调整后的 Fine-Gray 分析表明,与测量的 T50 一样,模型 A、B 或模型 C 得出的较低 eT50 值是全队列中新发心血管事件风险较高的独立预测因素。
我们从临床可用变量中开发了三个 eT50 方程。如果无法获得测量的 T50,这些 eT50 值可能会有用。